SCHEMBL3918264

SCHEMBL3918264

O=C1CN(c2ccc(Cc3nccs3)cc2OCc2ccccc2)S(=O)(=O)N1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 7/20 0.40
PTPN2 P17706 1/20 0.34
LTA4H P09960 1/20 0.33
INSR P06213 1/20 0.33
ALK Q9UM73 1/20 0.33
NR3C1 P04150 1/20 0.32
PTGER1 P34995 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
HPGD P15428 1/20 0.32
CYP2C19 P33261 1/20 0.32
APOBEC3G Q9HC16 1/20 0.32
CARM1 Q86X55 3/20 0.31
PRMT6 Q96LA8 1/20 0.31
PRMT1 Q99873 1/20 0.31
PRMT8 Q9NR22 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL646919 0.86 PTPN1 (0.47) PTPN1PTPN2ALDH1A1HPGD
SCHEMBL3918378 0.84 PTPN1 (0.45) PTPN1INSRALKCARM1PRMT6
SCHEMBL650084 0.81 PTPN1 (0.42) PTPN1PTPN2
SCHEMBL3219600 0.81 PTPN1 (0.49) PTPN1PTPN2LTA4H
SCHEMBL3926349 0.80 PTPN1 (0.45) PTPN1PTPN2PTGER1CYP1A2
SCHEMBL648884 0.80 PTPN1 (0.40) PTPN1PTPN2PTGER1ALDH1A1
SCHEMBL647267 0.79 MRGPRX4 (0.43) PTPN1PTGER1HPGD
SCHEMBL3917104 0.79 PTPN1 (0.46) PTPN1PTPN2PTGER1ALDH1A1CYP1A2
SCHEMBL3920465 0.79 PTPN1 (0.45) PTPN1PTGER1CYP1A2
SCHEMBL3929067 0.79 PTPN1 (0.45) PTPN1PTPN2PTGER1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8084448-B2 Organic compounds NOVARTIS AG (CH) 2011-12-27 US disclosed
US-20090181928-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-07-16 US disclosed
EP-2038267-A2 THIADIAZOLIDINONE INHIBITORS OF PTPASE Novartis AG (CH) 2009-03-25 EP disclosed
WO-2007115058-A2 THIADIAZOLIDINONE INHIBITORS OF PTPASE NOVARTIS AG (CH) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181928-A1 ORGANIC COMPOUNDS PTPRS, PTPRO, PTPRC PTPN1 21/4885PTPN2 5/4885LTA4H 1254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.